Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 44.0 %

Shares of Eagle Pharmaceuticals stock opened at $1.80 on Monday. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.37. The company’s fifty day simple moving average is $1.27 and its 200-day simple moving average is $0.96.

Institutional Trading of Eagle Pharmaceuticals

An institutional investor recently bought a new position in Eagle Pharmaceuticals stock. Jane Street Group LLC acquired a new stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 25,837 shares of the specialty pharmaceutical company’s stock, valued at approximately $96,000. Jane Street Group LLC owned approximately 0.20% of Eagle Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.